Endocardial fibro elastosis hinders left ventricular growth and prevents biventricular surgical repair for patients with congenital critical aortic stenosis and hypoplastic left heart syndrome. While surgical resection is currently the only available treatment option, EFE frequently recurs. Therefore, we aimed to investigate the mechanisms behind EFE and develop new therapeutic strategies using an animal model.
The main developments in the field of EndMT research are restricted to cell culture models which have inherent limitations, and research has been hampered due to a lack of in vivo models. Our group previously established that the underlying mechanism of EFE formation involves a phenotypical change of endocardial endothelial cells to fibroblasts, a process called endothelial to mesenchymal transition. This animal model allows for a more generalized examination of EndMT induced fibrosis in the heart, whereas other models are designed to induce EndMT through genetic modifications, hypertension, or dietary restrictions.
As EFE often recurs after primary resection, sometimes with an even more infiltrative growth pattern, we are especially interested in the molecular interaction with the underlying myocardium.